Advertisement

Topics

Articles about Biotechnology, Pharmaceutical and Healthcare

00:16 EDT 24th August 2016 | BioPortfolio

Latest Articles on life science, biotechnology, pharmaceutical and healthcare topics and current issues.

Showing News Articles 1–25 of 74,000+

Tuesday 23rd August 2016

[Articles] Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial

Gemcitabine plus cisplatin prolongs progression-free survival in patients with recurrent or metastatic nasopharyngeal carcinoma. The results establish gemcitabine plus cisplatin as the standard first-line treatment option for this population.

[Comment] Gemcitabine: a game changer in nasopharyngeal carcinoma

For decades, the platinum doublet of fluorouracil plus cisplatin reigned as the first-line chemotherapeutic combination for recurrent or metastatic nasopharyngeal carcinoma.1 Although whether fluorouracil plus cisplatin represents the most efficacious treatment strategy in this incurable subgroup of patients has always been contentious, in reality, no level 1 evidence existed to propose otherwise....

[Articles] Safety and efficacy of intravenous glyburide on brain swelling after large hemispheric infarction (GAMES-RP): a randomised, double-blind, placebo-controlled phase 2 trial

Intravenous glyburide was well tolerated in patients with large hemispheric stroke at risk for cerebral oedema. There was no difference in the composite primary outcome. Further study is warranted to assess the potential clinical benefit of a reduction in swelling by intravenous glyburide.

[Comment] Glyburide for cerebral oedema: could an old dog have a new trick?

Swelling of a large brain infarct portends transtentorial herniation and death. Yet, there are few effective prevention and treatment options. Reactive medical treatments, including osmotic drugs (eg, glycerol and mannitol) and corticosteroids, do not improve survival and functional outcome.1–3 Reactive decompressive craniectomy improves survival and functional outcome in some patients, but incr...

[Comment] What is the future of proof of concept studies in multiple sclerosis?

Multiple sclerosis is an inflammatory and neurodegenerative, autoimmune CNS disorder that is—at least in the early phase—amenable to treatment with various immunomodulatory drugs.1 The approval of the first oral drug for multiple sclerosis, the sphingosine-1-phosphate (S1P) receptor modulator fingolimod, for patients with relapsing–remitting multiple sclerosis, was a major advance and enrich...

Siphoning Samples from Single Cells

Like a minuscule blood test, a new method extracts samples from single cells, leaving the cell alive. Learn more...

Fighting Antibiotic Resistance Through Deeper Sequencing

Researchers developed a new technique to uncover rare mutations in the bacterial genome and used it to determine how certain antibiotics mutate DNA. How will this approach help combat antibiotic...

Brain cells restored by stem cell therapy following stroke, neurological diseases

SOURCE August 2016 When a person has a stroke, blood flow to the brain is interrupted, causing brain cells to die within minutes due to lack of oxygen. In some cases, this can result in paralysis, speech and language problems, vision problems, and memory loss. But in a new study, […]

For IVF embryos, lab chemicals can have lasting effects

The goop used to grow embryos in during in vitro fertilization may affect how well the process works, and experts want companies to more clearly label the ingredients in the…

Pfizer's Medivation acquisition boosts Clal Biotech

Medivation has signed an agreement to acquire Pidilizumab, an anti-cancer drug being developed by Clal Biotech-controlled CureTech.

EpiPen goes for the gold: Drug maker, under fire for price hikes, blitzed Olympics with ads

Mylan Pharmaceuticals, under fire for hiking the price of its EpiPen, bought nearly $2 million worth of airtime during NBC’s Olympics coverage.

Drug prices are kept high in US by protection and price negotiations, study finds

The high cost of prescription drugs in the United States is due in large part to the monopoly power granted to manufacturers through the drug and patent approval processes, together with restrictions...

Application of whole blood before staining improves outcomes of macular hole surgery

Application of whole blood followed by brilliant blue staining of the internal limiting membrane allowed earlier and better visual rehabilitation in macular hole surgery than conventional brilliant blue staining, a study found.“[This] could be attributed to earlier photoreceptor regeneration as evidenced by inner segment/outer segment junction continuity and increase in outer foveal thickness,...

Parents remain leery of schools that require HPV vaccination

Only 21 percent of parents believe that requiring students to be vaccinated for HPV is a good idea, a new study finds.

Johnson & Johnson announces ruling related to its infliximab biosimilar

Johnson & Johnson announced the District of Massachusetts Federal Court issued a ruling on the summary judgment motion filed by Celltrion Healthcare Co. Ltd., Celltrion Inc. and Hospira Healthcare Corporation in the infringement lawsuits filed by Janssen Biotech Inc. regarding Remicade.According to the release, the court ruled in favor of Celltrion and Hospira, noting that U.S. Patent No. 6,284,47...

Higher risk of infection found for patients with RA treated with IL-1 beta inhibitors

Recently published results showed patients with rheumatoid arthritis were more likely to experience invasive group A streptococcal infection if they were prescribed medications that inhibited interleukin-1 beta.Researchers analyzed the FDA database on adverse events for patients with rheumatoid arthritis (RA) who were prescribed anakinra.

Galapagos, Gilead Initiate Phase 3 Program for RA Drug

NewsThe FINCH program includes three studies with filgotinib.Topics: 

In long-awaited decision, labor board says graduate students can unionize at private universities

A labor board ruled that private universities must accept unions formed by graduate students who conduct research and help teach classes.

Foundation Medicine Adds New Immunotherapy Features to Product Pipeline

NewsTMB is reported as the total number of DNA mutations per megabase in a tumor sequence.

Cyon Therapeutics Granted Licensing Rights for Novartis's Anti-PCKS9 Antibody

NewsThe deal includes regulatory and commercial milestones. No financial details were released. Topics: 

How Advertisers Seduce Our Subconscious

In 1957 Vance Packard’s book The Hidden Persuaders shocked the world by revealing that messages exposed subliminally, below our level of perception, were able to increase sales of ice cream and Coke. The experiment he cited was later shown to be a hoax, but one of Packard’s other assertions, that advertising can influence us below our level of awareness, is absolutely true. In fact, rather sc...

Publication Exclusive: Good early results seen with pre-Descemet's endothelial keratoplasty in failed grafts

Graft failure in any situation can happen due to inherent defects in the donor graft or pre-existing pathology in the recipient. Inherent graft issues such as low endothelial cell count, surgical trauma to the graft and endothelial disease in the donor can cause early graft failure. Graft rejection is another main etiology that can happen, especially in full-thickness keratoplasty. Lamellar kerato...

Smartphone App Could Improve Antiretroviral Adherence Therapy for HIV Patients

NewsTheir findings were more surprising considering that the majority of the 26 study participants had never used a smartphone before.Contributed Author:&nbs

Zika anxiety leading some pregnant women to flee Miami

Some pregnant women have decided to leave Miami or are considering leaving to avoid getting infected with Zika virus.

Not So Fast on the PD-L1 Comparisons

We may have to rethink what we think about the recent trial in which Bristol-Myers Squibb’s Opdivo was ineffective in non-small cell lung cancer. The arguing has been about the status of the patients, specifically how much PD-L1 protein they were expressing. But writing in BioCentury, Stephen Hansen points out that comparing the various trials


Quick Search
Advertisement